The Nano-Intervention

Obesity and type 2 diabetes are closely interconnected metabolic disorders driven by complex molecular interactions involving adipose tissue dysfunction, chronic inflammation, impaired insulin signaling, mitochondrial abnormalities, and gut microbiome imbalance. Conventional therapeutic strategies often provide limited success because they primarily target downstream metabolic symptoms rather than the underlying molecular drivers. Nanotechnology has become a promising platform which can address these challenges by means of tailored and multifunctional therapeutic interventions. This chapter explores how nano-enabled strategies can disrupt vital molecular connections between obesity and diabetes. Particular attention is given to adipose tissue-targeted nanocarriers, inflammation-modulating nanomedicine, gene and RNA-based nano-therapeutics, mitochondria-directed nanoparticles, and microbiome-modulating nano-systems. Advances in precision nanomedicine, including stimuli-responsive nanocarriers and multi-target platforms, highlight the potential for metabolic reprogramming at the cellular level. Collectively, nano-interventions represent a transformative approach for developing next-generation therapies aimed at preventing and managing obesity-associated diabetes.

Hali tarjima qilinmagan